Abstract
The paper of Ragaz et al. ( 1 ) provides important level 1 evidence that the improvement in overall survival from the addition of postmastectomy radiotherapy to systemic therapy in axillary lymph node-positive patients, previously reported ( 2 ) , is sustained up to 20 years.